Table I.
Percentage of Event Reduction in Clinical Hypertension Trials in Older Patients: Average 12/5 mm Hg Systolic/Diastolic Reduction
| Stroke | CAD | CHF | All CVD | |
|---|---|---|---|---|
| Systolic/diastolic | ||||
| Australian | 33 | 18 | ‐ | 31 |
| EWPHE | 36 | 20 | 22 | 29* |
| STOP | 47* | 13† | 51* | 40* |
| MRC | 25* | 19 | ‐ | 17* |
| HDFP | 44* | 15* | ‐ | 16* |
| Isolated systolic | ||||
| SHEP | 33* | 27* | 55* | 32* |
| Syst‐Eur | 42* | 30 | 29 | 31* |
| Syst‐China | 38* | 27 | ‐ | 25* |
| CAD=coronary artery disease; CHF=congestive heart failure; CVD=cardiovascular disease; EWPHE=European Working Party on High Blood Pressure in the Elderly; STOP=Swedish Trial in Old Patients with Hypertension; MRC=Medical Research Council; HDFP=Hypertension Detection and Follow‐up Program Cooperative Group; SHEP=Systolic Hypertension in the Elderly Program; Syst‐Eur=Systolic Hypertension‐Europe trial; Syst‐China=Systolic Hypertension‐China trial; *statistically significant; † myocardial infarction only | ||||